
    
      The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14
      days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin,
      vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with
      B-cell lymphoma.
    
  